Patents Assigned to Pfizer Products Inc.
  • Patent number: 7638537
    Abstract: Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: December 29, 2009
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Patent number: 7635702
    Abstract: Novel imidazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: December 22, 2009
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Michael J. Munchhof, Laura C. Blumberg
  • Publication number: 20090215857
    Abstract: The present invention provides for compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder, depression, schizophrenia, and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (I) or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 29, 2006
    Publication date: August 27, 2009
    Applicant: Pfizer Products Inc.
    Inventors: Thomas Bruno Lanni, Scott Edward Lazerwith, Susan Mary Kult Sheehan, Anthony Jerome Thomas
  • Publication number: 20090186924
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Application
    Filed: March 19, 2009
    Publication date: July 23, 2009
    Applicants: Pfizer Inc., Pfizer Products Inc..
    Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
  • Patent number: 7538134
    Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: May 26, 2009
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
  • Publication number: 20090004221
    Abstract: The present invention provides a genetically modified PRRS virus which has been modified such that the conserved cysteine in the E protein has been deleted or changed to a non-cysteine residue and polynucleotides that encode it. Vaccines comprising the genetically modified virus and polynucleotides are also provided.
    Type: Application
    Filed: November 2, 2005
    Publication date: January 1, 2009
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Dongwan Yoo, Changhee Lee, Jay Gregory Calvert
  • Publication number: 20080311151
    Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.
    Type: Application
    Filed: May 12, 2008
    Publication date: December 18, 2008
    Applicants: PFIZER, INC., PFIZER PRODUCTS, INC.
    Inventors: John Morgan Hardham, Kendall Wayne King, Rajendra Krishnan, Kimberly Jean Dreier, David Ross McGavin, John David Haworth
  • Publication number: 20080286302
    Abstract: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic acids contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
    Type: Application
    Filed: April 4, 2008
    Publication date: November 20, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Siao-Kun Wan Welsh, Jay Gregory Calvert, Michael K. O'Hara, Xuemei Cao
  • Publication number: 20080275101
    Abstract: The present invention relates to solid salt forms of the 3-pyrrole substituted 2-indolinone compound 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide. It also relates to polymorphs of the phosphate salt of the amide. The invention further relates to the use of the salts and polymorphs in the treatment of protein kinase related disorders.
    Type: Application
    Filed: September 8, 2006
    Publication date: November 6, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Michael Hawley, Changquan C. Sun
  • Publication number: 20080275235
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)- signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Application
    Filed: July 23, 2008
    Publication date: November 6, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Publication number: 20080262107
    Abstract: Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.
    Type: Application
    Filed: May 18, 2005
    Publication date: October 23, 2008
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Walter C. Babcock, Dwayne T. Friesen, David Keith Lyon, Warren Kenyon Miller, Daniel Tod Smithey
  • Patent number: 7417041
    Abstract: Novel fused heteroaromatic compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-? signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases.
    Type: Grant
    Filed: February 20, 2004
    Date of Patent: August 26, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Laura C. Blumberg, Michael J. Munchhof, Andrei Shavnya
  • Publication number: 20080193439
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders, in particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
    Type: Application
    Filed: March 14, 2008
    Publication date: August 14, 2008
    Applicants: PFIZER, INC., PFIZER PRODUCTS, INC.
    Inventors: Mohamad A. Morsey, Tracy M. Brown
  • Publication number: 20080175860
    Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention relates to vaccines and methods for protecting dogs against disease caused by Leptospira bratislava. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 24, 2008
    Applicants: PFIZER INC., PFIZER PRODUCTS INC.
    Inventors: Joseph Frantz, Cassius McAllister Tucker, Thomas Jack Newby
  • Patent number: 7378101
    Abstract: The present invention relates to novel bacterial isolates identified by their 16S rRNA DNA, that cause periodontal disease in companion animals, polynucleotide sequences contained therein, polypeptides encoded by such polynucleotide sequences and vaccines comprising such bacteria, polynucleotides, or polypeptides. Also provided are methods for treating and preventing periodontal disease and kits for detecting and treating periodontal disease kits for detecting and preventing periodontal disease. In addition, methods for assessing the efficacy of a vaccine against periodontal diseases in an animal are provided.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: May 27, 2008
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: John Morgan Hardham, Kendall Wayne King, Rajendra Krishnan, Kimberly Jean Dreier, David Ross McGavin, John David Haworth
  • Patent number: 7378408
    Abstract: Formulations containing an antibacterial alkali metal salt of a cephalosporin compound and methods of treating bacterial infections in dogs and cats.
    Type: Grant
    Filed: November 12, 2002
    Date of Patent: May 27, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Roger N. Kimball, Renuka D. Reddy, Evgenyi Y. Shalaev
  • Patent number: 7361357
    Abstract: The present invention provides safe vaccines and methods of preparing such vaccines. The vaccines of the present invention contain at least two live mutant viruses of the same family or nucleic acid molecules encoding such viruses, wherein each of the two viruses or the encoding nucleic adds contains a mutation that confers a desirable phenotype and the mutations in the viruses reside in the same genomic site such that the mutant viruses cannot recombine with each other to eliminate the mutations.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: April 22, 2008
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Siao-Kun Wan Welch, Jay Gregory Calvert, Michael K. O'Hara, Xuemei Cao
  • Patent number: 7354941
    Abstract: Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0): wherein R5 and R6 are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 30, 2001
    Date of Patent: April 8, 2008
    Assignee: Pfizer Products Inc.
    Inventors: Anthony Marfat, Robert James Chambers
  • Publication number: 20080045504
    Abstract: This invention relates to novel amino substituted benzonitrile derivatives and to pharmaceutical compositions containing the novel amino substituted benzonitrile derivatives. This invention also relates to methods of treatment using amino substituted benzonitrile derivatives to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, and treat bone fracture and muscle damage in mammals, including humans.
    Type: Application
    Filed: April 29, 2005
    Publication date: February 21, 2008
    Applicant: PFIZER PRODUCTS INC.
    Inventors: Thomas Gant, Bruce Lefker, Hua Ke, James O'Malley, Roger Hill
  • Publication number: 20070298053
    Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
    Type: Application
    Filed: August 30, 2007
    Publication date: December 27, 2007
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventor: Paul Dominowski